The anti-inflammatory drug CNI-1493 regulates the intracellular processing of Aβ in different cell types of the brain

Recently, we have reported that the potent anti-inflammatory p38-MAPK-inhibitor CNI-1493 is capable to decrease the extracellular Aβ production in vitro (Bacher et al., J Exp Med. 2008). This phenomenon-was also confirmed by our in vivo experiment showing that the soluble Aβ fraction was markedly reduced in an APP transgenic mouse model following CNI-1493 administration. One possible explanation for the CNI-1493 dependent decrease of extracellular Aβ in cell culture supernatants or within the brain cytosol fraction is now being offered by our present study which showed a profound uptake of soluble Aβ species fol…